KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) Tax Provisions (2017 - 2018)

Palvella Therapeutics has reported Tax Provisions over the past 4 years, most recently at -$164000.0 for Q4 2018.

  • Quarterly Tax Provisions fell 213.89% to -$164000.0 in Q4 2018 from the year-ago period, while the trailing twelve-month figure was -$164000.0 through Sep 2019, down 4000.0% year-over-year, with the annual reading at $164000.0 for FY2020, N/A changed from the prior year.
  • Tax Provisions was -$164000.0 for Q4 2018 at Palvella Therapeutics, down from -$148000.0 in the prior quarter.
  • Over five years, Tax Provisions peaked at $814000.0 in Q2 2017 and troughed at -$164000.0 in Q4 2018.
  • The 4-year median for Tax Provisions is $40441.0 (2015), against an average of $110647.8.
  • The largest YoY upside for Tax Provisions was 118.18% in 2018 against a maximum downside of 213.89% in 2018.
  • A 4-year view of Tax Provisions shows it stood at -$18.0 in 2014, then soared by 908016.67% to $163425.0 in 2015, then dropped by 11.89% to $144000.0 in 2017, then crashed by 213.89% to -$164000.0 in 2018.
  • Per Business Quant, the three most recent readings for PVLA's Tax Provisions are -$164000.0 (Q4 2018), -$148000.0 (Q2 2018), and $144000.0 (Q4 2017).